{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:19:23Z","timestamp":1791343163878,"version":"4.3.1"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejim.2024.10.024","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T03:47:43Z","timestamp":1731124063000},"page":"15-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Translating evidence into practice: Managing electrolyte imbalances and iron deficiency in heart failure"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0724-7842","authenticated-orcid":false,"given":"Ryosuke","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Koziolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9818-042X","authenticated-orcid":false,"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.10.024_bib0001","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0002","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.10.024_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.14857","article-title":"2024 update in heart failure","author":"Beghini","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-024-01046-6","article-title":"Global epidemiology of heart failure","author":"Khan","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0005","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/heartjnl-2021-320131","article-title":"Prevalence, incidence and survival of heart failure: a systematic review","volume":"108","author":"Emmons-Bell","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2024.10.024_bib0006","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0007","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0008","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0009","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0010","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0011","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1838","article-title":"Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials","volume":"23","author":"von Haehling","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0012","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial","volume":"45","author":"von Haehling","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0013","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0014","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: data from the empire HF trial","volume":"25","author":"Fuchs Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jchf.2022.12.012","article-title":"Prevalent and incident anemia in PARADIGM-HF and the effect of Sacubitril\/Valsartan","volume":"11","author":"Curtain","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10741-015-9482-y","article-title":"Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications","volume":"20","author":"Urso","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2024.10.024_bib0017","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1313341","article-title":"An integrated view of potassium homeostasis","volume":"373","author":"Gumz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0019","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/ehf2.14661","article-title":"Epidemiology and risk factors for hyperkalaemia in heart failure","volume":"11","author":"Grobbee","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","article-title":"Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004667","article-title":"Electrophysiology of Hypokalemia and Hyperkalemia","volume":"10","author":"Weiss","year":"2017","journal-title":"Circul Arrhythmia Electrophysiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0022","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jacc.2003.06.021","article-title":"What is the optimal serum potassium level in cardiovascular patients?","volume":"43","author":"Macdonald","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0023","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0024","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10741-020-10039-9","article-title":"Serum potassium and heart failure: association, causation, and clinical implications","volume":"26","author":"Sfairopoulos","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2024.10.024_bib0025","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ehf2.12402","article-title":"Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK","volume":"6","author":"Linde","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219899","article-title":"Dyskalemia, its patterns, and prognosis among patients with incident heart failure: a nationwide study of US veterans","volume":"14","author":"Matsushita","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2024.10.024_bib0027","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/20009666.2019.1593778","article-title":"Influence of abnormal potassium levels on mortality among hospitalized heart failure patients in the US: data from National Inpatient Sample","volume":"9","author":"Basnet","year":"2019","journal-title":"J Commun Hosp Intern Med Perspect"},{"key":"10.1016\/j.ejim.2024.10.024_bib0028","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.1757","article-title":"Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish heart failure registry","volume":"22","author":"Cooper","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0029","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circul Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","article-title":"Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial","volume":"24","author":"Desai","year":"2018","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0031","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"N\u00fa\u00f1ez","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.10.024_bib0032","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ejhf.688","article-title":"Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia","volume":"19","author":"Rossignol","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0033","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jama.2024.17888","article-title":"Potassium supplementation and prevention of atrial fibrillation after cardiac surgery: the TIGHT K randomized clinical trial","volume":"332","author":"O'Brien","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.10.024_bib0034","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ejim.2024.10.024_bib0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejim.2024.03.021","article-title":"Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: a population-based analysis","volume":"125","author":"Jim\u00e9nez-Marrero","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0036","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0037","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ejhf.1079","article-title":"Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF","volume":"20","author":"Beusekamp","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0038","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/ejhf.1793","article-title":"Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0039","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovascul Pharmacother"},{"key":"10.1016\/j.ejim.2024.10.024_bib0040","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0042","article-title":"SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study","volume":"385","author":"Fu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2024.10.024_bib0043","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14779072.2024.2363395","article-title":"Targeting obesity for therapeutic intervention in heart failure patients","volume":"22","author":"Sato","year":"2024","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ejim.2024.10.024_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175174","article-title":"Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia","volume":"931","author":"Dong","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ehf2.14588","article-title":"The efficacy and safety of new potassium binders on renin-angiotensin-aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis","volume":"11","author":"Abuelazm","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0046","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","article-title":"Potassium binders for hyperkalemia in chronic kidney disease-diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis","volume":"95","author":"Palmer","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2024.10.024_bib0047","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0048","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0049","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ehf2.14268","article-title":"Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure","volume":"10","author":"Tardif","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0050","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/1573403X15666190306111812","article-title":"Hyponatremia in heart failure: pathogenesis and management","volume":"15","author":"Rodriguez","year":"2019","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.ejim.2024.10.024_bib0051","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11897-024-00651-3","article-title":"Evaluation and management of hyponatremia in heart failure","volume":"21","author":"Mondellini","year":"2024","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.ejim.2024.10.024_bib0052","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.021733","article-title":"Predicting sudden death in patients with mild to moderate chronic heart failure","volume":"90","author":"Kearney","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2024.10.024_bib0053","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/archinte.167.18.1998","article-title":"Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial","volume":"167","author":"Gheorghiade","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0054","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3810\/pgm.2009.03.1991","article-title":"Economic impact of hyponatremia in hospitalized patients: a retrospective cohort study","volume":"121","author":"Callahan","year":"2009","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0055","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.12659\/MSM.898538","article-title":"Hyponatremia, cognitive function, and mobility in an outpatient heart failure population","volume":"22","author":"Albabtain","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ejim.2024.10.024_bib0056","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/ehf2.14302","article-title":"Long-term outcomes in heart failure with preserved ejection fraction: predictors of cardiac and non-cardiac mortality","volume":"10","author":"Shahim","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0057","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/ehf2.14472","article-title":"Admission hyponatraemia as heart failure events predictor in patients with acute heart failure","volume":"10","author":"Sarastri","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0058","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jacc.2014.12.010","article-title":"Hyponatremia in acute decompensated heart failure: depletion versus dilution","volume":"65","author":"Verbrugge","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0059","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4330\/wjc.v6.i12.1252","article-title":"Arginine vasopressin as a target in the treatment of acute heart failure","volume":"6","author":"Gilotra","year":"2014","journal-title":"World J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0060","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0008-6363(01)00328-5","article-title":"Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects","volume":"51","author":"Bankir","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2024.10.024_bib0061","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","article-title":"Increased plasma arginine vasopressin levels in patients with congestive heart failure","volume":"1","author":"Goldsmith","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2005.03.003","article-title":"Neurohormonal activation in congestive heart failure and the role of vasopressin","volume":"95","author":"Chatterjee","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0063","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0008-6363(01)00297-8","article-title":"Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin","volume":"51","author":"Kalra","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2024.10.024_bib0064","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","article-title":"Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system","volume":"7","author":"Creager","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.112.970012","article-title":"Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial","volume":"6","author":"Lanfear","year":"2013","journal-title":"Circul Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0066","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","article-title":"Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative","volume":"31","author":"Ronco","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0067","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.jacc.2005.11.084","article-title":"Renal impairment and outcomes in heart failure: systematic review and meta-analysis","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0068","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ejhf.35","article-title":"The kidney in congestive heart failure: \u2018are natriuresis, sodium, and diuretics really the good, the bad and the ugly?","volume":"16","author":"Verbrugge","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0069","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0002-9343(82)90823-3","article-title":"Disorders of urinary concentration and dilution","volume":"72","author":"Jamison","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0070","doi-asserted-by":"crossref","first-page":"F923","DOI":"10.1152\/ajprenal.00192.2006","article-title":"Regulation of cation transport in the distal nephron by mechanical forces","volume":"291","author":"Satlin","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0071","first-page":"175","article-title":"Thiazide-associated hyponatremia in the elderly: what the clinician needs to know","volume":"13","author":"Liamis","year":"2016","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0072","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial","volume":"44","author":"Trull\u00e0s","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1751-7133.2008.00037.x","article-title":"Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion","volume":"15","author":"Ali","year":"2009","journal-title":"Congest Heart Fail (Greenwich, Conn)"},{"key":"10.1016\/j.ejim.2024.10.024_bib0074","doi-asserted-by":"crossref","first-page":"782","DOI":"10.7326\/0003-4819-100-6-782","article-title":"Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition","volume":"100","author":"Packer","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0075","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/ejhf.2873","article-title":"Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the ESC-HFA EORP heart failure long-term registry","volume":"25","author":"Kap\u0142on-Cie\u015blicka","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0076","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00392-021-01853-8","article-title":"Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial","volume":"111","author":"Martens","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0077","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0078","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0079","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/heartjnl-2021-320277","article-title":"Hyponatraemia in heart failure: time for new solutions?","volume":"108","author":"Kap\u0142on-Cie\u015blicka","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2024.10.024_bib0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1681\/ASN.2019090944","article-title":"A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis","volume":"31","author":"Refardt","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0081","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.10.024_bib0082","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","article-title":"Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan","volume":"19","author":"Hauptman","year":"2013","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0083","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0084","doi-asserted-by":"crossref","first-page":"e00614","DOI":"10.1002\/prp2.614","article-title":"Tolvaptan add-on therapy in patients with acute heart failure: a systematic review and meta-analysis","volume":"8","author":"Luo","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ejim.2024.10.024_bib0085","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ejhf.2001","article-title":"Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a\/V2 receptor antagonist in experimental heart failure","volume":"23","author":"Mondritzki","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0086","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7150\/ijbs.20074","article-title":"Vasopressin mediates the renal damage induced by limited fructose rehydration in recurrently dehydrated rats","volume":"13","author":"Garc\u00eda-Arroyo","year":"2017","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.ejim.2024.10.024_bib0087","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","article-title":"Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"42","author":"Domanski","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0088","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","article-title":"Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0089","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","article-title":"Relation of loop diuretic dose to mortality in advanced heart failure","volume":"97","author":"Eshaghian","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/clc.23286","article-title":"Lower urine sodium predicts longer length of stay in acute heart failure patients: insights from the ROSE AHF trial","volume":"43","author":"Cunningham","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0091","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/ejhf.1753","article-title":"Clinical importance of urinary sodium excretion in acute heart failure","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0092","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0093","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1388-9842(00)00094-5","article-title":"Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure","volume":"2","author":"Paterna","year":"2000","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0094","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jchf.2019.10.012","article-title":"Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center's experience","volume":"8","author":"Griffin","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0095","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/ehf2.14720","article-title":"Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure","volume":"11","author":"Cobo Marcos","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0096","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cardfail.2019.03.007","article-title":"Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the heart failure society of America scientific statements committee","volume":"25","author":"Vest","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0097","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00059-015-4345-9","article-title":"Effects of limiting fluid intake on clinical and laboratory outcomes in patients with heart failure. Results of a meta-analysis of randomized controlled trials","volume":"41","author":"De Vecchis","year":"2016","journal-title":"Herz"},{"key":"10.1016\/j.ejim.2024.10.024_bib0098","doi-asserted-by":"crossref","DOI":"10.3390\/nu13041136","article-title":"Magnesium: biochemistry, nutrition, detection, and social impact of diseases linked to its deficiency","volume":"13","author":"Fiorentini","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ejim.2024.10.024_bib0099","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/jcsm.13450","article-title":"Total magnesium intake and risk of frailty in older women","volume":"15","author":"Struijk","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ejim.2024.10.024_bib0100","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archinte.1985.00360040073017","article-title":"Frequency of hypomagnesemia in hospitalized patients receiving digitalis","volume":"145","author":"Whang","year":"1985","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0101","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.0954-6820.1986.tb18112.x","article-title":"Intracellular electrolytes in cardiac failure","volume":"707","author":"Wester","year":"1986","journal-title":"Acta Medica Scand Suppl"},{"key":"10.1016\/j.ejim.2024.10.024_bib0102","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1023\/A:1022950321817","article-title":"Hypomagnesemia and hypermagnesemia","volume":"4","author":"Topf","year":"2003","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ejim.2024.10.024_bib0103","first-page":"989","article-title":"Potassium depletion and salt-sensitive hypertension in Dahl rats: effect on calcium, magnesium, and phosphate excretions","volume":"17","author":"Wu","year":"1995","journal-title":"Clin Exp Hyperten (New York, NY : 1993)"},{"key":"10.1016\/j.ejim.2024.10.024_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(92)91357-A","article-title":"Electrolyte balance in heart failure and the role for magnesium ions","volume":"70","author":"Wester","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.ackd.2018.02.010","article-title":"Magnesium and Cardiovascular Disease","volume":"25","author":"Tangvoraphonkchai","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ejim.2024.10.024_bib0106","article-title":"The ECG characteristics of patients with isolated hypomagnesemia","volume":"11","author":"Yang","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0107","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0002-8703(84)90572-6","article-title":"Magnesium: nature's physiologic calcium blocker","volume":"108","author":"Iseri","year":"1984","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0108","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1113\/jphysiol.2003.048538","article-title":"Regulation of L-type calcium current by intracellular magnesium in rat cardiac myocytes","volume":"555","author":"Wang","year":"2004","journal-title":"J Physiol (Lond)"},{"key":"10.1016\/j.ejim.2024.10.024_bib0109","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12916-016-0742-z","article-title":"Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies","volume":"14","author":"Fang","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0110","article-title":"Relation of magnesium intake with cardiac function and heart failure hospitalizations in black adults: the jackson heart study","volume":"9","author":"Taveira","year":"2016","journal-title":"Circul Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0111","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/0002-9149(93)90986-M","article-title":"Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease","volume":"72","author":"Bashir","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0112","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijcard.2008.05.006","article-title":"Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study","volume":"136","author":"Adamopoulos","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0113","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0735-1097(10)80329-8","article-title":"Prognostic importance of the serum magnesium concentration in patients with congestive heart failure","volume":"16","author":"Gottlieb","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijcard.2009.01.047","article-title":"Magnesium orotate in severe congestive heart failure (MACH)","volume":"134","author":"Stepura","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0115","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nri3863","article-title":"Iron homeostasis in host defence and inflammation","volume":"15","author":"Ganz","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0116","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.bbadis.2018.08.030","article-title":"Role of iron metabolism in heart failure: from iron deficiency to iron overload","volume":"1865","author":"Zhang","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.ejim.2024.10.024_bib0117","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJM199912233412607","article-title":"Disorders of iron metabolism","volume":"341","author":"Andrews","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0118","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2010.06.028","article-title":"Two to tango: regulation of Mammalian iron metabolism","volume":"142","author":"Hentze","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejim.2024.10.024_bib0119","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/labinvest.2017.111","article-title":"Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology","volume":"98","author":"Vela","year":"2018","journal-title":"Lab Invest"},{"key":"10.1016\/j.ejim.2024.10.024_bib0120","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MCHD-0037-2016","article-title":"Macrophages and iron metabolism","volume":"4","author":"Ganz","year":"2016","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ejim.2024.10.024_bib0121","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1007\/s00018-009-0051-1","article-title":"Mammalian iron transport","volume":"66","author":"Anderson","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ejim.2024.10.024_bib0122","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure","volume":"31","author":"Jankowska","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0123","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/ehf2.13265","article-title":"Iron deficiency in heart failure","volume":"8","author":"Loncar","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0124","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/jcsm.12927","article-title":"Iron deficiency is related to low functional outcome in patients at early rehabilitation after acute stroke","volume":"13","author":"Doehner","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ejim.2024.10.024_bib0125","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/jcsm.13277","article-title":"Iron deficiency is related to lower muscle mass in community-dwelling individuals and impairs myoblast proliferation","volume":"14","author":"Vinke","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ejim.2024.10.024_bib0126","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/cvr\/cvn301","article-title":"Energy metabolism in heart failure and remodelling","volume":"81","author":"Ingwall","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2024.10.024_bib0127","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1139\/H09-013","article-title":"Exercise training, energy metabolism, and heart failure","volume":"34","author":"Ventura-Clapier","year":"2009","journal-title":"Appl Physiol Nutr Metabol = Physiol Appl, Nutrition Metab"},{"key":"10.1016\/j.ejim.2024.10.024_bib0128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrcardio.2015.109","article-title":"Iron deficiency and cardiovascular disease","volume":"12","author":"von Haehling","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0129","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/eurheartj\/ehac569","article-title":"Iron deficiency and cardiovascular disease","volume":"44","author":"Savarese","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0130","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0131","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ehf2.12209","article-title":"Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)","volume":"4","author":"Saitoh","year":"2017","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0132","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/jcsm.13291","article-title":"Prognostic impact of cachexia by multi-assessment in older adults with heart failure: FRAGILE-HF cohort study","volume":"14","author":"Maekawa","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ejim.2024.10.024_bib0133","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1002\/jcsm.13355","article-title":"Anorexia of aging: an international assessment of healthcare providers' knowledge and practice gaps","volume":"14","author":"Aprahamian","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ejim.2024.10.024_bib0134","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2018-05-815944","article-title":"Iron deficiency","volume":"133","author":"Camaschella","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2024.10.024_bib0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1620\/tjem.235.69","article-title":"Liver congestion in heart failure contributes to inappropriately increased serum hepcidin despite anemia","volume":"235","author":"Ohno","year":"2015","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0136","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.ejim.2024.10.024_bib0137","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126493","article-title":"Hepcidin-ferroportin interaction controls systemic iron homeostasis","volume":"22","author":"Nemeth","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2024.10.024_bib0138","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.124.068883","article-title":"Redefining iron deficiency in patients with chronic heart failure","volume":"150","author":"Packer","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.10.024_bib0139","article-title":"Management of iron deficiency in heart failure: practical considerations and implementation of evidence-based iron supplementation","author":"Kido","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0140","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.10.024_bib0141","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.10.024_bib0142","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ejhf.2810","article-title":"Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis","volume":"25","author":"Graham","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0143","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.024_bib0144","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","article-title":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis","volume":"44","author":"Ponikowski","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0145","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12311","article-title":"Guideline for the laboratory diagnosis of functional iron deficiency","volume":"161","author":"Thomas","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0146","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for iron deficiency in patients with heart failure","volume":"79","author":"Masini","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0147","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/eurheartj\/ehae086","article-title":"Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial","volume":"45","author":"Cleland","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0148","article-title":"Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients","volume":"11","author":"Grote Beverborg","year":"2018","journal-title":"Circul Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.ejim.2024.10.024_bib0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.10.024_bib0151","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.bbagen.2011.07.014","article-title":"Non-transferrin bound iron: a key role in iron overload and iron toxicity","volume":"1820","author":"Brissot","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejim.2024.10.024_bib0152","first-page":"ehae560","article-title":"Is myocardial accumulation of non-transferrin-bound iron clinically relevant?","author":"von Haehling","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0153","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae359","article-title":"Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway","author":"Vera-Aviles","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.10.024_bib0154","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia","volume":"168","author":"Beck-da-Silva","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0155","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.10.024_bib0156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117383","article-title":"Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis","volume":"10","author":"Tolkien","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2024.10.024_bib0157","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1016\/j.jacc.2024.03.431","article-title":"Intravenous iron repletion for patients with heart failure and iron deficiency: JACC state-of-the-art review","volume":"83","author":"Cheema","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0158","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ejhf.2092","article-title":"Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study","volume":"23","author":"Karavidas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0159","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ejhf.2894","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12872-022-02647-0","article-title":"Effects of Sacubitril\/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction","volume":"22","author":"Bolla","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2024.10.024_bib0161","first-page":"174","article-title":"C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients","volume":"10","author":"Valentim Goncalves","year":"2020","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2024.10.024_bib0162","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2022.07.048","article-title":"Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role","volume":"367","author":"Fu","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0163","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0164","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ejhf.2132","article-title":"Effect of dapagliflozin on anaemia in DAPA-HF","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0165","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/ehf2.14742","article-title":"Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction","volume":"11","author":"Docherty","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0166","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ejhf.2766","article-title":"Little at a time: trying to understand the battery of benefits of sodium-glucose contransporter 2 inhibitors in heart failure","volume":"25","author":"von Haehling","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0167","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10741-017-9615-6","article-title":"Phosphate imbalance in patients with heart failure","volume":"22","author":"Christopoulou","year":"2017","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2024.10.024_bib0168","doi-asserted-by":"crossref","DOI":"10.3390\/nu13041215","article-title":"Role of creatine in the heart: health and disease","volume":"13","author":"Balestrino","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ejim.2024.10.024_bib0169","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1530-0277.1987.tb01274.x","article-title":"Hypophosphatemia and hypomagnesemia result in cardiovascular dysfunction: theoretical basis for alcohol-induced cellular injury","volume":"11","author":"Brautbar","year":"1987","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.ejim.2024.10.024_bib0170","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/clc.4960190905","article-title":"Hemodynamic effects of creatine phosphate in patients with congestive heart failure: a double-blind comparison trial versus placebo","volume":"19","author":"Ferraro","year":"1996","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0171","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejcts.2004.03.004","article-title":"Hypophosphatemia following open heart surgery: incidence and consequences","volume":"26","author":"Cohen","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ejim.2024.10.024_bib0172","first-page":"19","volume":"12","author":"Schwartz","year":"2014"},{"key":"10.1016\/j.ejim.2024.10.024_bib0173","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fphys.2013.00247","article-title":"Pathophysiological roles of FGF signaling in the heart","volume":"4","author":"Itoh","year":"2013","journal-title":"Front Physiol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0174","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1161\/CIRCHEARTFAILURE.114.001272","article-title":"Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease","volume":"7","author":"Wannamethee","year":"2014","journal-title":"Circul Heart Fail"},{"key":"10.1016\/j.ejim.2024.10.024_bib0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.ackd.2006.10.006","article-title":"Clinical assessment of vascular calcification","volume":"14","author":"Raggi","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ejim.2024.10.024_bib0176","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1681\/ASN.2008020141","article-title":"Serum phosphorus levels associate wit4h coronary atherosclerosis in young adults","volume":"20","author":"Foley","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0177","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1681\/ASN.2008040349","article-title":"Association of serum phosphate with vascular and valvular calcification in moderate CKD","volume":"20","author":"Adeney","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2024.10.024_bib0178","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524004448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524004448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T21:33:05Z","timestamp":1736026385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524004448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":178,"alternative-id":["S0953620524004448"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.10.024","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translating evidence into practice: Managing electrolyte imbalances and iron deficiency in heart failure","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}